BR112023018758A2 - Intensificação de cicatrização de ferida com anticorpos anticeramida - Google Patents

Intensificação de cicatrização de ferida com anticorpos anticeramida

Info

Publication number
BR112023018758A2
BR112023018758A2 BR112023018758A BR112023018758A BR112023018758A2 BR 112023018758 A2 BR112023018758 A2 BR 112023018758A2 BR 112023018758 A BR112023018758 A BR 112023018758A BR 112023018758 A BR112023018758 A BR 112023018758A BR 112023018758 A2 BR112023018758 A2 BR 112023018758A2
Authority
BR
Brazil
Prior art keywords
wound
intensification
antibodies
anticeramide
wound healing
Prior art date
Application number
BR112023018758A
Other languages
English (en)
Portuguese (pt)
Inventor
Julia Busik
Richard Kolesnick
Original Assignee
Univ Michigan State
Memorial Hospital For Cancer And Allied Diseases
Memorial Sloan Kettering Cancer Center
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan State, Memorial Hospital For Cancer And Allied Diseases, Memorial Sloan Kettering Cancer Center, Sloan Kettering Inst Cancer Res filed Critical Univ Michigan State
Publication of BR112023018758A2 publication Critical patent/BR112023018758A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023018758A 2021-03-16 2022-03-15 Intensificação de cicatrização de ferida com anticorpos anticeramida BR112023018758A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163161758P 2021-03-16 2021-03-16
PCT/US2022/020385 WO2022197703A1 (en) 2021-03-16 2022-03-15 Wound healing enhancement with anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
BR112023018758A2 true BR112023018758A2 (pt) 2023-11-28

Family

ID=83321040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018758A BR112023018758A2 (pt) 2021-03-16 2022-03-15 Intensificação de cicatrização de ferida com anticorpos anticeramida

Country Status (10)

Country Link
US (1) US20240158487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308231A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511079A (cg-RX-API-DMAC7.html)
KR (1) KR20230162788A (cg-RX-API-DMAC7.html)
CN (1) CN117320750A (cg-RX-API-DMAC7.html)
BR (1) BR112023018758A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212333A1 (cg-RX-API-DMAC7.html)
IL (1) IL305920A (cg-RX-API-DMAC7.html)
MX (1) MX2023010858A (cg-RX-API-DMAC7.html)
WO (1) WO2022197703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12655229B2 (en) 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152287B1 (en) * 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
SG11201700787XA (en) * 2014-08-07 2017-02-27 Sloan Kettering Inst Cancer Anti-ceramide antibodies
US12655229B2 (en) * 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Also Published As

Publication number Publication date
CA3212333A1 (en) 2022-09-22
CN117320750A (zh) 2023-12-29
MX2023010858A (es) 2023-11-23
WO2022197703A1 (en) 2022-09-22
US20240158487A1 (en) 2024-05-16
IL305920A (en) 2023-11-01
EP4308231A4 (en) 2025-01-29
KR20230162788A (ko) 2023-11-28
JP2024511079A (ja) 2024-03-12
EP4308231A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
BR112022017986A2 (pt) Anticorpos anticoronavírus e métodos de uso
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
BR112022022523A2 (pt) Anticorpos contra sars-cov-2
BR112022023088A2 (pt) Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos
AR115418A1 (es) ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
BR112015032690A2 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
ECSP21022299A (es) Anticuerpos de anti-cd33 y métodos para usarlos
CL2025001913A1 (es) Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso.
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
BR112021011351A2 (pt) Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
BR112023018450A2 (pt) Anticorpo monoclonal anti-cd47 e seu uso
MX2024015304A (es) Terapias combinadas con un anticuerpo antifactor xi/factor xia
MX2024008933A (es) Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares.
MX2024009153A (es) Metodos para el tratamiento de sujetos con psoriasis en placas del cuero cabelludo
BR112022016368A2 (pt) Anticorpos pilra e seus métodos de uso
BR112014016950A2 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
BR112021021077A2 (pt) Métodos de diagnóstico e tratamento de artrite reumatoide